Compare SOPH & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | XOMA |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | SOPH | XOMA |
|---|---|---|
| Price | $5.05 | $32.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $60.60 |
| AVG Volume (30 Days) | 94.1K | ★ 106.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | $24.95 |
| Revenue Next Year | $19.57 | $6.20 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $18.40 |
| 52 Week High | $5.70 | $39.92 |
| Indicator | SOPH | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 74.86 |
| Support Level | $4.54 | $32.73 |
| Resistance Level | $5.31 | $35.17 |
| Average True Range (ATR) | 0.29 | 1.64 |
| MACD | 0.03 | 0.43 |
| Stochastic Oscillator | 56.26 | 86.15 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.